Drug Trial Radar · NCT03237182
The Individualized M(X) Drug-resistant TB Treatment Strategy Study
Last checked: Nov 20, 2026Latest source record: Sep 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
205
Actual
Start
Jun 14, 2017
Primary completion
Dec 19, 2022
Study completion Dec 19, 2022
Sponsor
- Lead sponsor
- Centre for the AIDS Programme of Research in South AfricaResearch network
- Sponsor type
- Research network
- First posted
- Aug 2, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized controlled clinical trial comparing treatment success of a gene-derived individualized drug-resistant Tuberculosis regimen to a standard Tuberculosis regimen based on South African National Tuberculosis guidelines.
Conditions
- Tuberculosis, Multidrug-Resistant
Interventions
Individualized TB treatment with multiple drugsDrug
Patients with drug-resistant TB will receive a combination of any of the following drugs based on whole genome sequencing: rifampicin, rifabutin, isoniazid, high dose isoniazid, pyrazinamide, ethambutol, levofloxacin, moxifloxacin, ofloxacin, gatifloxacin, amikacin, capreomycin, kanamycin, streptomycin, ethionamide, prothionamide, cycloserine, terizidone, pretomanid, linezolid, sutezolid, clofazimine, bedaquiline, delaminid, para-aminosalicylic acid, imipenem/cilastatin, meropenem, amoxicillin/clavulanate, clarithromycin, azithromycin and thioacetazone
Standardized TB treatment with multiple drugsDrug
Patients with drug-resistant TB with receive a combination of any of the following drugs based on South African Department of Health guidelines: rifampicin, rifabutin, isoniazid, high dose isoniazid, pyrazinamide, ethambutol, levofloxacin, moxifloxacin, ofloxacin, gatifloxacin, amikacin, capreomycin, kanamycin, streptomycin, ethionamide, prothionamide, cycloserine, terizidone, pretomanid, linezolid, sutezolid, clofazimine, bedaquiline, delaminid, para-aminosalicylic acid, imipenem/cilastatin, meropenem, amoxicillin/clavulanate, clarithromycin, azithromycin and thioacetazone
Primary outcomes
What the sponsor says the trial is designed to measure.
- Culture negative survival rateTime frame: 24 months
- Culture negative survival rateTime frame: 30 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
King Dinuzulu Hospital
Durban, KwaZulu-Natal, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.